Management of cSSTIs:the role of daptomycin

References

• Doern GV, Jones RN, Pfaller MA, et al. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). Diagn Microbiol Infect Dis 1999;34:65–72
   PubMed Web of Science ®Google Scholar
• Lewis RT. Soft tissue infections. World J Surg 1998;22:146–51
   PubMed Web of Science ®Google Scholar
• DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 2004;53\(Suppl 2):ii37–50
   Google Scholar
• Menichetti F. Current and emerging serious Gram-positive infections. Clin Microbiol Infect 2005;11(Suppl 3):22–8
   PubMedGoogle Scholar
• Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001;45: 1919–22
   Google Scholar
• Critchley IA, Draghi DC, Sahm DF, et al. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000–2001. J Antimicrob Chemother 2003;51:639–49
   PubMed Web of Science ®Google Scholar
• Fluit AC, Schmitz FJ, Verhoef J, et al. Daptomycin in vitro susceptibility in European Gram-positive clinical isolates. Int J Antimicrob Agents 2004;24:59–66
   PubMed Web of Science ®Google Scholar
• Fluit AC, Schmitz FJ, Verhoef J, et al. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother 2004;48:1007–11
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Bradford PA, Weiss WJ, et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 2002;46:2595–601
   PubMed Web of Science ®Google Scholar
• Richter SS, Kealey DE, Murray CT, et al. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 2003;52:123–7
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Hershberger E, Moldovan T, et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000;44:1062–6
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA, et al. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 2000;44:3447–50
   PubMed Web of Science ®Google Scholar
• Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004;53: 669–74
   Google Scholar
• Oleson FB, Jr., Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000;44:2948–53
   PubMed Web of Science ®Google Scholar
• Jung D, Rozek A, Okon M, et al. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol 2004;11:949–57
   PubMed Web of Science ®Google Scholar
• Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:2538–44
   Google Scholar
• Sader HS, Streit JM, Fritsche TR, et al. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide. Diagn Microbiol Infect Dis 2004;50:201–4
   PubMed Web of Science ®Google Scholar
• Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002;49:467–70
   Web of Science ®Google Scholar
• Lamp KC, Rybak MJ, Bailey EM, et al. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother 1992;36:2709–14
   PubMed Web of Science ®Google Scholar
• LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004;48:4665–72
   PubMed Web of Science ®Google Scholar
• Tedesco KL, Rybak MJ. Daptomycin. Pharmacotherapy 2004;24:41–57
   PubMed Web of Science ®Google Scholar
• Silverman JA, Oliver N, Andrew T, et al. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001;45: 1799–802
   PubMed Web of Science ®Google Scholar
• Hirschwerk D, Ginocchio CC, Bythrow M, et al. Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2006;27:315–7
   PubMed Web of Science ®Google Scholar
• Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006;44:595–7
   PubMed Web of Science ®Google Scholar
• Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006;44:655–6
   PubMed Web of Science ®Google Scholar
• Hayden MK, Rezai K, Hayes RA, et al. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005;43:5285–7
   PubMed Web of Science ®Google Scholar
• Vikram HR, Havill NL, Koeth LM, et al. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 2005;43:5384–7
   PubMed Web of Science ®Google Scholar
• Mangili A, Bica I, Snydman DR, et al. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005;40:1058–60
   PubMed Web of Science ®Google Scholar
• Dandekar PK, Tessier PR, Williams P, et al. Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model. Chemotherapy 2004;50:11–6
   PubMed Web of Science ®Google Scholar
• Dandekar PK, Tessier PR, Williams P, et al. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 2003;52:405–11
   PubMed Web of Science ®Google Scholar
• Louie A, Kaw P, Liu W, et al. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2001;45:845–51
   PubMed Web of Science ®Google Scholar
• Dvorchik BH, Brazier D, DeBruin MF, et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47:1318–23
   PubMed Web of Science ®Google Scholar
• Steenbergen JN, Alder J, Thorne GM, et al. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005;55:283–8
   PubMed Web of Science ®Google Scholar
• Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38:994–1000
   PubMed Web of Science ®Google Scholar
• Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Investig Drugs 2004;13:1159–69
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Rybak MJ, Rhomberg PR, et al. Evaluation of daptomycin, telavancin, and vancomycin activity in the presence of albumin or serum. Presented at 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, 16–19 December 2005
   Google Scholar
• Craig WA, Kiem S, Andes DR. Effect of protein binding on the antimicrobial activity of daptomycin in sera and albumin solution. Presented at the 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, 30 September–3 October 2004
   Google Scholar
• Woodworth JR, Nyhart EH, Jr., Brier GL, et al. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992;36:318–25
   Google Scholar
• Dvorchik B. Moderate liver impairment has no influence on daptomycin pharmacokinetics. J Clin Pharmacol 2004;44:715–22
   PubMed Web of Science ®Google Scholar
• Dvorchik B, Damphousse D. Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers. J Clin Pharmacol 2004;44:612–20
   PubMed Web of Science ®Google Scholar
• Cubicin Summary of Product Characteristics 2006. Available from http://www.emea.eu.int/humandocs/Humans/EPAR/cubicin/cubicin.htm [Last accessed 23rd June 2006]
   Google Scholar
• Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 2005;45:48–56
   PubMed Web of Science ®Google Scholar
• Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact 2004;150: 137–47
   Google Scholar
• Tally FP, Zeckel M, Wasilewski MM, et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs 1999;8:1223–38
   PubMedGoogle Scholar
• Woodworth JR, Nyhart EH, Wolny JD, et al. Tobramycin and daptomycin disposition when co-administered to healthy volunteers. J Antimicrob Chemother 1994;33:655–9
   PubMed Web of Science ®Google Scholar
• LaPlante KL, Rybak MJ. Daptomycin – a novel antibiotic against Gram-positive pathogens. Expert Opin Pharmacother 2004;5:2321–31
   PubMed Web of Science ®Google Scholar
• Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653–65
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673–81
   PubMed Web of Science ®Google Scholar
• Chiron DAP data on file 003
   Google Scholar
• Matthews PA, DeBruin MF. Faster resolution of clinical signs (CSx) in complicated skin and soft tissue infection (cSSTI) by daptomycin (DAP) vs. standard therapy (STND) in a randomized, blinded, comparative study. Presented at 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, USA, 25–28 October 2001
   Google Scholar
• Owens RC, Lamp KC, Russo R, et al. Post marketing experience with daptomycin (DAP) for the treatment of skin and skin structure infections (SSSI). Presented at 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA, 16–19 December 2005
   Google Scholar
• Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149–52
   PubMed Web of Science ®Google Scholar
• Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006;26: 347–52
   Google Scholar
• von Eiff C, Jansen B, Kohnen W, et al. Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs 2005;65:179–214
   PubMed Web of Science ®Google Scholar
• Vaudaux P, Francois P, Bisognano C, et al. Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother 2003;52:89–95
   PubMed Web of Science ®Google Scholar
• Schaad HJ, Bento M, Lew DP, et al. Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection. BMC Infect Dis 2006;6:74
   PubMedGoogle Scholar
• Rao N, Regalla DM. Uncertain efficacy of daptomycin for prosthetic joint infections. Clin Orthop Relat Res 2006; May 25 [Epub ahead of print]
   Google Scholar
• Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2006;49: 2735–45
   Web of Science ®Google Scholar
• Sakoulas G, Eliopoulos GM, Alder J, et al. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003;47: 1714–8
   PubMed Web of Science ®Google Scholar
• Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004;53:530–2
   PubMed Web of Science ®Google Scholar
• Bingen E, Lambert-Zechovsky N, Leclercq R, et al. Bactericidal activity of vancomycin, daptomycin, ampicillin and amino-glycosides against vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1990;26:619–26
   PubMed Web of Science ®Google Scholar
• Akins RL, Rybak MJ. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother 2000;44: 1925–9
   PubMed Web of Science ®Google Scholar
• Burns CA. Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy. Scand J Infect Dis 2006;38:133–6
   PubMed Web of Science ®Google Scholar
• European Public Assessment Report for CUBICIN. Available from http://www.emea.eu.int/humandocs/Humans/EPAR/cubicin/cubicin.htm [Last accessed 23rd June 2006]
   Google Scholar